Reply With Quotehttp://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a4.htm
Serious adverse events and deaths were evaluated in a pooled safety analysis that included 29,953 females aged 10 through 72 years (16,142 received HPV2). Proportions of persons reporting a serious adverse event were similar in vaccine and control groups (5.3% and 5.9%, respectively), as were the types of serious adverse events reported (5). In the pooled safety analysis, including 12,533 women who received HPV2 and over 10,730 in the control groups, incidence of potential new autoimmune disorders did not differ (0.8% in both groups).
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a5.htm
As observed previously with females, in the clinical trials for males, the most common adverse events were injection-site reactions, most of which were mild or moderate in intensity (5). Headache and fever were the most commonly reported systemic adverse reactions in both treatment groups (5). Postlicensure data in females indicate that HPV4 adverse events are similar to adverse events reported following administration of other vaccines to adolescents (6).
There are clearly many soruces of information by now, but in essence apart from local reactions other adverse effects are not different to placebo. Such is the double blind trial and registry cohort data, if people choose not to believe evidence then they are beyond help
Bookmarks